Tag: Prescription Drugs
Improved Outcomes Seen With Ibrutinib in Chronic Lymphocytic Leukemia
Time to next treatment was improved for first-line ibrutinib versus chemoimmunotherapy in match-adjusted analyses
Angiotensin Receptor Blocker Use Linked to Lower Incidence of Epilepsy
Findings seen in patients with no preexisting history of stroke or cardiovascular disease in subgroup analyses
ViPOR Results in Durable Remission in Specific Subtypes of Lymphoma
Complete responses seen in 38 percent of patients, all with non-GCB DLBCL, high-grade B-cell lymphoma with rearrangements of MYC and BCL2 or BCL6
Reteplase Superior to Alteplase Within 4.5 Hours of Ischemic Stroke
Reteplase more likely to result in excellent functional outcome than alteplase for ischemic stroke within 4.5 hours of symptom onset
FDA Approves Augtyro for NTRK-Positive Advanced Solid Tumors
Approval is for both TKI-naive and TKI-pretreated patients across solid tumor types
Dementia With Lewy Bodies Risk Down With α-1 Adrenergic Receptor Antagonists
Risk for developing DLB was lower for men newly started on Tz/Dz/Az compared with those taking tamsulosin or 5ARI
Trametinib Safe, Effective for Juvenile Myelomonocytic Leukemia
Seven of 10 children with relapsed or refractory JMML completed all 12 cycles of therapy or used trametinib as bridge to HSCT
Lebrikizumab Tied to Sustained Atopic Dermatitis Treatment Effect
Findings seen despite negligible remaining lebrikizumab serum concentrations following treatment withdrawal
Continuing Metformin in Pregnancy Has Little Effect on Nonlive Birth
Little to no increased risk for nonlive birth seen among women continuing metformin and adding insulin versus switching to insulin monotherapy
Paternal Metformin Use Not Linked to Major Congenital Malformations
No significant association seen for increased risk for MCMs with metformin in monotherapy, but association suggested for metformin in polytherapy
